CR20170208A - Agonistas parciales del receptor de insulina - Google Patents
Agonistas parciales del receptor de insulinaInfo
- Publication number
- CR20170208A CR20170208A CR20170208A CR20170208A CR20170208A CR 20170208 A CR20170208 A CR 20170208A CR 20170208 A CR20170208 A CR 20170208A CR 20170208 A CR20170208 A CR 20170208A CR 20170208 A CR20170208 A CR 20170208A
- Authority
- CR
- Costa Rica
- Prior art keywords
- partial agonists
- insulin receptor
- receptor partial
- insulin
- dimers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se divulgan dímeros de insulina y dímeros de análogo de insulina que actúan como agonistas parciales en el receptor de insulina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082857P | 2014-11-21 | 2014-11-21 | |
| US201562242503P | 2015-10-16 | 2015-10-16 | |
| PCT/US2015/061445 WO2016081670A2 (en) | 2014-11-21 | 2015-11-19 | Insulin receptor partial agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170208A true CR20170208A (es) | 2017-07-17 |
Family
ID=54838417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170208A CR20170208A (es) | 2014-11-21 | 2015-11-19 | Agonistas parciales del receptor de insulina |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10017556B2 (es) |
| EP (4) | EP3666792B1 (es) |
| JP (5) | JP6484337B2 (es) |
| KR (2) | KR102049647B1 (es) |
| CN (2) | CN112494656B (es) |
| AR (1) | AR102712A1 (es) |
| AU (3) | AU2015349890B2 (es) |
| CA (2) | CA3014641C (es) |
| CL (3) | CL2017001288A1 (es) |
| CO (1) | CO2017004976A2 (es) |
| CR (1) | CR20170208A (es) |
| DO (1) | DOP2017000124A (es) |
| EA (1) | EA036714B1 (es) |
| ES (2) | ES3004386T3 (es) |
| GT (1) | GT201700104A (es) |
| IL (1) | IL252257A0 (es) |
| MX (3) | MX2017006651A (es) |
| NI (1) | NI201700060A (es) |
| PE (1) | PE20170957A1 (es) |
| PH (1) | PH12017500935A1 (es) |
| SG (4) | SG11201704064TA (es) |
| SV (1) | SV2017005445A (es) |
| TN (1) | TN2017000178A1 (es) |
| TW (1) | TW201625673A (es) |
| WO (1) | WO2016081670A2 (es) |
| ZA (1) | ZA201703238B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170077A (es) | 2014-08-04 | 2017-06-26 | Nuevolution As | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |
| TN2017000178A1 (en) | 2014-11-21 | 2018-10-19 | Merck Sharp & Dohme | Insulin receptor partial agonists |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| EP3922260A3 (en) * | 2016-05-24 | 2022-06-15 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
| US10689430B2 (en) | 2016-05-25 | 2020-06-23 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
| MA46568A (fr) * | 2016-10-24 | 2019-08-28 | Novo Nordisk As | Dosage biologique de formulations d'insuline |
| US10919949B2 (en) | 2017-08-17 | 2021-02-16 | Novo Nordisk A/S | Acylated insulin analogues and uses thereof |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CN112898172B (zh) * | 2019-12-04 | 2022-05-31 | 中国科学院大连化学物理研究所 | 可被羧肽酶酶解的双亲和功能团化合物的合成方法 |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| UY38994A (es) | 2019-12-20 | 2021-07-30 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2022046747A1 (en) * | 2020-08-26 | 2022-03-03 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
| EP4204441A4 (en) * | 2020-08-26 | 2025-01-08 | Merck Sharp & Dohme LLC | Insulin receptor partial agonists |
| EP4208173A4 (en) * | 2020-09-03 | 2025-11-26 | Dyne Therapeutics Inc | PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIC COMPLEXES |
| CN116457015A (zh) * | 2020-09-03 | 2023-07-18 | 达因疗法公司 | 制备蛋白质-寡核苷酸复合物的方法 |
| EP4210729A4 (en) * | 2020-09-09 | 2025-01-01 | Merck Sharp & Dohme LLC | PARTIAL INSULIN RECEPTOR AGONISTS |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1381273A (en) * | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3907763A (en) | 1972-03-01 | 1975-09-23 | Bayer Ag | Insulin derivatives crosslinked by a dicarboxylic acid moiety |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5304473A (en) | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
| WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
| EP0741188A3 (en) | 1995-05-05 | 1999-07-14 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| EP1085879A2 (en) * | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding agents that modulate the 5-ht transporter |
| DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US7105314B2 (en) | 2001-04-02 | 2006-09-12 | Novo Nordisk A/S | Method for making human insulin precursors |
| JP4638225B2 (ja) | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| KR100507796B1 (ko) | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
| EP1692168B1 (en) | 2003-12-03 | 2011-07-20 | Novo Nordisk A/S | Single-chain insulin |
| US20090197800A1 (en) | 2004-10-27 | 2009-08-06 | Novo Nordisk A/S | Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| JP2008533100A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | Ｐｅｇ化された単鎖インスリン |
| US20090069216A1 (en) | 2006-02-21 | 2009-03-12 | Novo Nordisk A/S | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof |
| JP2009530243A (ja) | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー／エス | アシル化単鎖インスリン |
| WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| WO2007104734A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| WO2007104737A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US9505823B2 (en) | 2006-08-07 | 2016-11-29 | TEV A Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
| WO2008145721A2 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| EP2296692A4 (en) | 2008-04-22 | 2012-06-06 | Univ Case Western Reserve | ISOFORM-SPECIFIC INSULIN ANALOG |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| RS59913B1 (sr) * | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| JP5789515B2 (ja) | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2011059895A1 (en) | 2009-11-11 | 2011-05-19 | Quest Diagnostics Investments Incorporated | Hexa mutations |
| JP5969469B2 (ja) * | 2010-06-16 | 2016-08-17 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト |
| US8255297B2 (en) | 2010-07-20 | 2012-08-28 | Facebook, Inc. | Creation, redemption, and accounting in a virtual currency system |
| WO2012049307A2 (en) | 2010-10-15 | 2012-04-19 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| KR20150021011A (ko) * | 2011-10-27 | 2015-02-27 | 케이스 웨스턴 리저브 유니버시티 | 초고도 농축된, 속효성 인슐린 유사체 제형 |
| EP3395358B1 (en) * | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| US20160067212A1 (en) | 2013-03-15 | 2016-03-10 | Universite De Geneve | Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production |
| KR20160065930A (ko) * | 2013-10-04 | 2016-06-09 | 머크 샤프 앤드 돔 코포레이션 | 글루코스-반응성 인슐린 접합체 |
| EP3068443B1 (en) * | 2013-11-12 | 2019-04-10 | Centre for Probe Development and Commercialization | Residualizing linkers and uses thereof |
| CR20160376A (es) | 2014-01-20 | 2016-10-07 | Hanmi Pharm Ind Co Ltd | Insulina de acción prolongada y uso de la misma |
| TN2017000178A1 (en) * | 2014-11-21 | 2018-10-19 | Merck Sharp & Dohme | Insulin receptor partial agonists |
-
2015
- 2015-11-19 TN TN2017000178A patent/TN2017000178A1/en unknown
- 2015-11-19 JP JP2017526961A patent/JP6484337B2/ja active Active
- 2015-11-19 CR CR20170208A patent/CR20170208A/es unknown
- 2015-11-19 CA CA3014641A patent/CA3014641C/en active Active
- 2015-11-19 KR KR1020177016516A patent/KR102049647B1/ko active Active
- 2015-11-19 US US14/945,461 patent/US10017556B2/en active Active
- 2015-11-19 CA CA2966765A patent/CA2966765C/en active Active
- 2015-11-19 SG SG11201704064TA patent/SG11201704064TA/en unknown
- 2015-11-19 ES ES19211801T patent/ES3004386T3/es active Active
- 2015-11-19 EP EP19211801.6A patent/EP3666792B1/en active Active
- 2015-11-19 SG SG10201809457YA patent/SG10201809457YA/en unknown
- 2015-11-19 SG SG10201809427SA patent/SG10201809427SA/en unknown
- 2015-11-19 SG SG10201809428UA patent/SG10201809428UA/en unknown
- 2015-11-19 KR KR1020197016746A patent/KR102101136B1/ko active Active
- 2015-11-19 PE PE2017000888A patent/PE20170957A1/es unknown
- 2015-11-19 AR ARP150103770A patent/AR102712A1/es unknown
- 2015-11-19 EP EP15807730.5A patent/EP3221343B1/en active Active
- 2015-11-19 CN CN202011335828.4A patent/CN112494656B/zh active Active
- 2015-11-19 WO PCT/US2015/061445 patent/WO2016081670A2/en not_active Ceased
- 2015-11-19 AU AU2015349890A patent/AU2015349890B2/en active Active
- 2015-11-19 EA EA201791117A patent/EA036714B1/ru unknown
- 2015-11-19 US US15/527,363 patent/US20170355743A1/en not_active Abandoned
- 2015-11-19 EP EP19211799.2A patent/EP3660041B1/en active Active
- 2015-11-19 PH PH12017500935A patent/PH12017500935A1/en unknown
- 2015-11-19 CN CN201580074165.6A patent/CN108064173B/zh active Active
- 2015-11-19 EP EP19211793.5A patent/EP3660040B1/en active Active
- 2015-11-19 MX MX2017006651A patent/MX2017006651A/es unknown
- 2015-11-19 TW TW104138282A patent/TW201625673A/zh unknown
- 2015-11-19 ES ES19211799T patent/ES2946247T3/es active Active
-
2017
- 2017-05-10 ZA ZA2017/03238A patent/ZA201703238B/en unknown
- 2017-05-11 IL IL252257A patent/IL252257A0/en unknown
- 2017-05-18 CO CONC2017/0004976A patent/CO2017004976A2/es unknown
- 2017-05-18 CL CL2017001288A patent/CL2017001288A1/es unknown
- 2017-05-19 NI NI201700060A patent/NI201700060A/es unknown
- 2017-05-19 DO DO2017000124A patent/DOP2017000124A/es unknown
- 2017-05-19 MX MX2020014121A patent/MX2020014121A/es unknown
- 2017-05-19 GT GT201700104A patent/GT201700104A/es unknown
- 2017-05-19 SV SV2017005445A patent/SV2017005445A/es unknown
- 2017-05-19 MX MX2020014120A patent/MX2020014120A/es unknown
-
2018
- 2018-06-13 US US16/007,046 patent/US10183981B2/en active Active
- 2018-07-31 AU AU2018211207A patent/AU2018211207B2/en active Active
- 2018-07-31 AU AU2018211208A patent/AU2018211208B2/en active Active
- 2018-09-28 JP JP2018183314A patent/JP2019014734A/ja not_active Withdrawn
- 2018-09-28 JP JP2018183315A patent/JP6943825B2/ja active Active
- 2018-09-28 JP JP2018183316A patent/JP6703068B2/ja active Active
- 2018-11-26 US US16/199,774 patent/US10800827B2/en active Active
-
2019
- 2019-04-26 CL CL2019001144A patent/CL2019001144A1/es unknown
- 2019-04-26 CL CL2019001143A patent/CL2019001143A1/es unknown
- 2019-11-12 JP JP2019204409A patent/JP6931033B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000124A (es) | Agonistas parciales del receptor de insulina | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| ECSP17015977A (es) | Terapia de combinacion | |
| IN2015DE00625A (es) | ||
| FR3023171B1 (fr) | Autoinjecteur. | |
| FR3023170B1 (fr) | Autoinjecteur. | |
| ECSP17039183A (es) | Agonistas parciales del receptor de insulina | |
| EA201991576A1 (ru) | Частичные агонисты инсулинового рецептора | |
| GT201700043S (es) | Pico para lavaplatos | |
| TN2014000468A1 (fr) | اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها | |
| TN2014000355A1 (fr) | طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية | |
| ES1119305Y (es) | Lámpara de mesa | |
| TN2014000377A1 (fr) | طائرة كهربائية كاتمة للصوت | |
| GT201400039S (es) | Diseño de bici-motocicleta | |
| ITCE20140004U1 (it) | Salvabimbi del dr. cirillo | |
| TN2014000384A1 (fr) | نظام صوتي ذكي وآمن | |
| CR20140455S (es) | Grua de portico | |
| CL2014003446S1 (es) | Mesa. | |
| ES1106783Y (es) | Mesa de cultivo | |
| NI201500033S (es) | Chainsaw ms382-1119 | |
| TN2014000388A1 (fr) | منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة | |
| TN2014000354A1 (fr) | جهاز مبتكر لتلقيح النخيل | |
| CR20140458S (es) | Grúa de pórtico | |
| GT201400012S (es) | Eco-estufa ahorradora de leña g.n.g | |
| IN2014CH00927A (es) |